A groundbreaking study from the University of Alberta used AI and “network medicine” to map extraintestinal conditions in 30,000+ inflammatory bowel disease (IBD) patients. Published in npj Digital Medicine, the research reveals that 57% of IBD patients suffer from additional autoimmune, mental health, or cardiovascular conditions—often overlooked in routine GI care.Led by gastroenterologist Dr. Daniel C. Baumgart, the project offers an interactive tool to help clinicians screen beyond the gut, reinforcing that IBD is a systemic inflammatory disorder, not just a GI issue.
Author: Abhay Panchal
Physicians face unique financial and legal risks—making early estate planning essential, not optional. In this practical guide, financial advisor John S. Gardner outlines the must-haves: revocable and irrevocable trusts, asset protection strategies, succession planning for medical practices, and tools like durable powers of attorney. Key insight: Start early. Planning ahead allows for better tax efficiency, stronger asset protection, and a lasting legacy—especially as estate tax exemptions are set to shrink by 2026. Gardner, whose wife is a gastroenterologist, emphasizes: “Estate planning isn’t just for the wealthy—it’s how you protect your purpose.”
Private equity interest in physician practices is surging—but before signing any deal, physician-owners should dig deeper. In a conversation with Jonathan Leffert, MD, attorney Peter A. Bogdanow outlines key questions to ask in the discovery phase: Bogdanow emphasizes: successful deals aren’t just about payout—they depend on alignment, transparency, and the operational strength of the platform’s MSO.
A recent study in Gastroenterology Nursing analyzed the top TikTok videos on IBD, revealing that 83% were personal stories, often touching on ostomies, advocacy, and disease management. Despite the platform’s popularity among young adults with IBD, none of the most-viewed content came from healthcare providers. The study found poor quality scores overall—signaling a major opportunity for clinicians to engage and educate directly through this powerful medium.
In May, Lawrence Kim, MD, began his term as the 120th president of the American Gastroenterological Association Institute. A private practice partner based in Denver, Dr. Kim has spent years prioritizing diversity in gastroenterology and spearheading the creation of a joint venture in gastrointestinal pathology, helping to establish South Denver Gastroenterology as one of the founding groups of the Digestive Health Physicians Association, the first organization focused on advocacy for independent gastroenterology practices.Dr. Kim spoke with Becker’s about his efforts in the GI space and his plans for his term as AGA president.
The AGA has released a living guideline for ulcerative colitis (UC), reshaping treatment protocols as new therapies emerge. Key updates include refined treatment algorithms, disease severity stratification, and guidance on step-up/step-down therapy. Dr. Adam Gluskin, a gastroenterologist with GI Alliance of Illinois, emphasizes the need for continuous learning as rapid drug approvals outpace clinical workflows and insurance adoption. Staying current is essential as precision medicine and emerging treatments begin to redefine UC care.
A groundbreaking care model is reshaping how we treat inflammatory bowel disease (IBD). Through a collaborative effort between UPMC, Cleveland Clinic, and Mount Sinai, the Specialty Medical Home (SMH) approach integrates gastroenterology, nutrition, and behavioral health into a unified care team. At the forefront: Dr. Eva Szigethy, a psychiatrist specializing in gastropsychiatry, and Dr. Benjamin Cohen, gastroenterologist at Cleveland Clinic. Together, they’re addressing the gut-brain connection head-on—recognizing that anxiety, depression, and stress can worsen IBD outcomes just as much as inflammation can.
Fecal microbiota transplants (FMT), once heralded as a miracle fix for gut-related diseases, may come with unintended consequences, according to new research from the University of Chicago published in Cell. While FMT is FDA-approved only for recurrent C. difficile infections, it’s increasingly being explored for conditions like IBD, obesity, diabetes, and even autism. But researchers led by Dr. Eugene Chang and Dr. Orlando DeLeon warn that transplanting microbes from the colon into other gut regions—like the small intestine—can result in mismatched colonization, metabolic shifts, and even behavioral changes. The study found that these “regional mismatches” persist for months and may…
In a wide-ranging Gut Check podcast hosted by Dr. Brian Lacy (Mayo Clinic), gastroenterologist Dr. Micheal Tadros (Albany Med Health System) dives into the expanding GI implications of GLP-1 receptor agonists—drugs like Ozempic, Wegovy, and Mounjaro. Once used primarily for diabetes, these agents are now reshaping care for obesity, fatty liver disease, and more. Dr. Tadros discusses not only their proven weight loss benefits (up to 20%) but also the cascade of GI side effects—including nausea, delayed gastric emptying, and gallbladder complications—that now land these patients in endoscopy suites. He highlights a nuanced, individualized approach to pre-procedure guidance, balancing aspiration…
In a sharp, practical analysis for HealthLeaders, Eric Wicklund unpacks how AI is quietly reshaping healthcare from the inside out. In the June 11, 2025 piece, leaders from Saint Peter’s Healthcare System and OSF HealthCare reveal how AI is being deployed in real clinical environments—automating documentation, bridging SDOH care gaps, and flagging patients at risk through video monitoring and predictive analytics. Crucially, AI is proving most valuable when it doesn’t get in the way—surfacing insights at the point of care, freeing up clinician bandwidth, and improving workflows without disrupting them. The article also tackles the evolving idea of ROI: in…